Steven Cohen’s Apogee Therapeutics APGE Stock Holding History

Steven Cohen’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.24M	Buy	+54,559	New	+$4.92M	0.01%	1506
2025 Q3	–	Sell	-1,230,377	Closed	-$53.4M	–	2295
2025 Q2	$53.4M	Buy	1,230,377 +837,889	+213%	+$31.9M	0.1%	239
2025 Q1	$14.7M	Buy	392,488 +89,753	+30%	+$3.47M	0.03%	544
2024 Q4	$13.7M	Sell	302,735 -404,533	-57%	-$20.6M	0.03%	592
2024 Q3	$41.5M	Buy	707,268 +438,036	+163%	+$21M	0.11%	226
2024 Q2	$10.6M	Sell	269,232 -217,968	-45%	-$10.6M	0.03%	594
2024 Q1	$32.4M	Sell	487,200 -221,200	-31%	-$9.66M	0.08%	307
2023 Q4	$19.8M	Buy	708,400 +335,292	+90%	+$6.72M	0.05%	427
2023 Q3	$7.95M	Buy	+373,108	New	+$8.22M	0.02%	727

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Steven Cohen's APGE Position: Q2 2026 in Review

Steven Cohen opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 54,559 shares worth $7.24M. The stake represents 0.01% of the portfolio and ranks #1506 among its holdings. This is a return to the name: Steven Cohen previously reported a position in APGE as recently as Q2 2025.

Steven Cohen first reported a position in APGE in Q3 2023 and has held it in 9 quarters since. The position peaked at $53.4M in Q2 2025. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Steven Cohen held 54,559 shares of Apogee Therapeutics worth $7.24M as of Q2 2026.
Apogee Therapeutics was a new Steven Cohen position in Q2 2026.
Apogee Therapeutics made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1506 holding.
Steven Cohen first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 9 quarters since.
Steven Cohen's Apogee Therapeutics position peaked at $53.4M in Q2 2025.
285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.